We are live on ! Find out more
EU

Emory University Portfolio holdings

AUM $267M
1-Year Est. Return 48.26%
This Fund
S&P 500
This Quarter Est. Return
+8.01%
1 Year Est. Return
+48.26%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$140M
AUM Growth
+$23.5M
Cap. Flow
+$20.7M
Cap. Flow %
14.77%
Top 10 Hldgs %
45.63%
Holding
53
New
9
Increased
27
Reduced
8
Closed
7

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$2.77M
2
SAGE
Sage Therapeutics
SAGE
+$2.74M
3
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$2.66M
4
XLRN
Acceleron Pharma
XLRN
+$2.65M
5
IFRX icon
InflaRx
IFRX
+$2.39M

Top Sells

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$1.88M
2
BKR icon
Baker Hughes
BKR
+$1.87M
3
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$1.84M
4
TSRO
TESARO, Inc.
TSRO
+$1.69M
5
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$1.68M

Sector Composition

Rank Sector Weight
1 Healthcare 53.45%
2 Financials 29.17%
3 Consumer Discretionary 3.76%
4 Technology 3.25%
5 Industrials 2.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BRK.A icon
1
Berkshire Hathaway Class A
BRK.A
$1.06T
$35M 24.99%
117
– –
JD icon
2
JD.com
JD
$41B
$5.04M 3.6%
124,490
+50
+0% +$2.27K
MYOV
3
DELISTED
Myovant Sciences Ltd.
MYOV
$3.75M 2.68%
176,387
+45,024
+34% +$685K
ONC
4
BeOne Medicines Ltd
ONC
$32.7B
$3.22M 2.3%
19,170
-2,786
-13% -$377K
ASND icon
5
Ascendis Pharma A/S
ASND
$17.1B
$3.07M 2.19%
46,933
-3,880
-8% -$218K
BPMC
6
DELISTED
Blueprint Medicines
BPMC
$2.95M 2.11%
+32,163
New +$2.77M
KALA icon
7
KALA BIO
KALA
$14.2M
$2.81M 2%
71
+31
+78% +$1.18M
AVXS
8
DELISTED
AveXis, Inc. Common Stock
AVXS
$2.78M 1.98%
22,474
+4,000
+22% +$475K
PBYI icon
9
Puma Biotechnology
PBYI
$430M
$2.66M 1.9%
39,066
+22,022
+129% +$1.65M
ABLX
10
DELISTED
Ablynx NV
ABLX
$2.63M 1.88%
+48,194
New +$2.39M
IFRX icon
11
InflaRx
IFRX
$283M
$2.62M 1.87%
+90,761
New +$2.39M
SAGE
12
DELISTED
Sage Therapeutics
SAGE
$2.6M 1.86%
+16,132
New +$2.74M
FOLD
13
DELISTED
Amicus Therapeutics
FOLD
$2.6M 1.85%
172,666
+37,302
+28% +$568K
TVTX icon
14
Travere Therapeutics
TVTX
$5.29B
$2.57M 1.84%
115,136
+30,251
+36% +$720K
NBIX icon
15
Neurocrine Biosciences
NBIX
$17.4B
$2.55M 1.82%
30,725
+5,780
+23% +$488K
ZGNX
16
DELISTED
Zogenix, Inc.
ZGNX
$2.54M 1.82%
63,499
+14,656
+30% +$581K
ALNY icon
17
Alnylam Pharmaceuticals
ALNY
$35.7B
$2.54M 1.81%
21,316
+6,972
+49% +$899K
INCY icon
18
Incyte
INCY
$23.4B
$2.54M 1.81%
30,447
+13,401
+79% +$1.21M
NGNE icon
19
Neurogene
NGNE
$744M
$2.52M 1.8%
8,958
+438
+5% +$121K
SGEN
20
DELISTED
Seagen Inc. Common Stock
SGEN
$2.52M 1.8%
48,079
+16,396
+52% +$893K
BMRN icon
21
BioMarin Pharmaceuticals
BMRN
$11.5B
$2.5M 1.78%
30,823
+8,686
+39% +$745K
GHDX
22
DELISTED
Genomic Health, Inc.
GHDX
$2.49M 1.78%
79,591
+16,665
+26% +$553K
XLRN
23
DELISTED
Acceleron Pharma
XLRN
$2.44M 1.74%
+62,410
New +$2.65M
ALXN
24
DELISTED
Alexion Pharmaceuticals
ALXN
$2.43M 1.73%
21,793
+5,020
+30% +$600K
CORI
25
DELISTED
Corium International, Inc.
CORI
$2.42M 1.72%
210,559
+42,506
+25% +$513K
1
2 3

Similar funds

CFG
Cambridge Financial Group Columbus, Ohio $267M AUM 31.62% 1-Year Est. Return
PC
Packer & Co Cottesloe, Australia $267M AUM
ALC
Alexander Labrunerie & Co Columbia, Missouri $267M AUM 21.24% 1-Year Est. Return
TWM
TCFG Wealth Management Laguna Niguel, California $267M AUM 39.78% 1-Year Est. Return
IP
Indigo Partners Phoenix, Arizona $267M AUM 9% 1-Year Est. Return
SP
ShawSpring Partners Boston, Massachusetts $268M AUM 28.19% 1-Year Est. Return
EAIC
Empower Annuity Insurance Company Hartford, Connecticut $268M AUM 0.28% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

Emory University's Q1 2018 Portfolio in Review

As of Q1 2018, Emory University held 53 positions worth $140M, up 20% from $117M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Emory University deployed $20.7M of net new capital in Q1 2018, opening 9 new positions and adding to 27 existing holdings. Its largest new stake was Blueprint Medicines: 32,163 shares worth $2.95M.

By sector, the portfolio is most concentrated in Healthcare at 53% of assets, up from 45% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was Wave Life Sciences, an estimated $636K trimmed.

  • Emory University's largest Q1 2018 buy was Blueprint Medicines: 32,163 shares worth $2.95M.
  • Emory University added most to Puma Biotechnology in Q1 2018, an estimated $1.65M increase.
  • Emory University's biggest Q1 2018 reduction was Wave Life Sciences, cutting an estimated $636K.
  • Emory University fully exited BioCryst Pharmaceuticals in Q1 2018, selling an estimated $1.88M.
  • Emory University's ten largest holdings make up 46% of its $140M portfolio in Q1 2018.
  • Emory University opened 9 new positions and closed 7 in Q1 2018.
  • Emory University's portfolio value rose 20% quarter-over-quarter to $140M.

Based on Emory University's 13F filing for Q1 2018, filed 14 May 2018.